On June 26th, the Institute for Gene Therapies hosted its second Congressional Briefing focused on the promise of gene therapy, its impact on patients, particularly the sickle cell patient community, and the role of Congress in helping to ensure patients can benefit from these transformational therapies. IGT Executive Director Mike Capaldi and IGT Scientific, Academic, and Medical Council Chair Dr. Donna Christensen moderated the discussion with the following speakers:
Shanetta Richardson, Sickle Cell Disease Patient Advocate
Regina Hartfield, President & CEO, Sickle Cell Disease Association of America
Dr. James Taylor, Director of Howard University College of Medicine's Center for Sickle Cell Disease
John Feore, IGT Policy Director
Watch the discussion here: